Gene targeting to tumors using adenoviral (Ad) vectors holds great potential for cancer imaging and therapy, but the limited efficacy of current methods used to improve delivery to target tissues and reduce unwanted interactions remain substantial barriers to further development. Progress in characterizing the set of molecular interactions used by Ad vectors to infect particular tissues has aided the development of novel strategies for retargeting vectors to tumor cells. One method is chemical retargeting of adenovirus using bispecific antibodies (bsAbs) against both viral capsid proteins and tumor-specific cell surface molecules. This approach can be combined either with competitive inhibitors designed to reduce viral tropism in undesired tissues, or with traditional therapeutics to increase the expression of surface molecules for improved tumor targeting. Ablating liver cell-specific interactions through mutation of capsid proteins or chemical means are promising strategies for reducing adenovirus-induced liver toxicity. The nature of tumor neovasculature also influences Ad delivery, and the use of vascular disrupting agents (VDAs) such as combretastatin can help elucidate these contributions. In this investigation, we evaluate a variety of these methods for retargeting Ad vectors to tumor cells in vitro and in vivo, and assess the contributions of specific molecular and tissue interactions that affect Ad transgene delivery.
Introduction
Gene therapy holds great promise for a variety of diagnostic and therapeutic applications, and adenoviral (Ad) technology has emerged as one of the primary approaches for the targeted delivery of genes to mammalian cells. Replication-deficient Ad vectors based on serotype five show excellent gene transfer efficiency, have high stability in vivo, can be grown to high titers, and techniques for their construction, propagation and purification are also well established. 1 Ad vectors have been used in the majority of all clinical trials evaluating gene therapy for cancer, and only rarely result in any serious complications. Results from trials using nontargeted adenovirus, however, have been generally disappointing. 2 This failure has mainly been attributed to the broad native tropism of Ad vectors, which occurs primarily through high-affinity binding of the Ad fiber knob domain to its primary cellular receptor, the widely expressed coxsackie and adenovirus receptor (CAR). 3 Other interactions are also involved in native Ad infection, including those between the RGD ligand in the penton base and a V b 3 and a V b 5 integrins, interactions between the KKTK sequence in the Ad fiber shaft and heparin sulfate glycosaminoglycans (HSGs), 4, 5 and binding of the Ad hexon protein to blood coagulation factors (VII and X), which serve as a bridge for HSPG-mediated hepatocyte transduction. [6] [7] [8] [9] [10] In vivo, the liver is a primary site of Ad infection due to hepatocyte transduction and Kuppfer-cell uptake, leading to greater than 95% of hepatocytes being transduced following intravenous administration. 11 This high level of liver tropism poses numerous problems for the development of Ad technology as a therapeutic or imaging modality directed to other tissues, including lower viral efficacy in target tissues and virus-induced liver inflammation and toxicity. 2 A primary goal of Ad cancer therapy is therefore to simultaneously reduce liver transduction (detargeting) and improve the specificity of transgene expression in target tissues such as tumors and their surrounding microenvironment (targeting). Previous studies indicate that CAR and integrin-mediated interactions are unlikely to be the primary mechanisms of liver infection, as Ad vectors with modifications designed to ablate CAR and integrin-mediated binding have shown high residual levels of liver transduction in vivo. 12 Recent data, however, indicate that changing the HSGbinding site in the fiber shaft can enhance cancer-cell infectivity while reducing liver transduction. 13 A more effective strategy might involve blocking the coagulation factor-hexon interactions using anti-coagulant therapy such as warfarin or nematode anticoagulant protein c2 (NapC2), 7, [14] [15] [16] or through mutation of the Ad hexon hypervariable regions. 8, 16, 17 Numerous approaches have been evaluated for detargeting and targeting Ad vectors. Ad vectors are typically detargeted using genetic modification of one or more of the three capsid proteins, hexon, penton and fiber, although chemical methods for transductional control incorporating bispecific adaptor molecules have also been used to effectively detarget adenovirus from their native tropism and retarget the virus to specific tissues. Bispecific fusion proteins or antibodies containing a high-affinity knob-binding component that ablates CAR binding are attached either covalently or through a chemical linker to another component with high specificity for a surface molecule on the target cell. Successful retargeting of vectors has been achieved using anti-knob antibodies or truncated CAR constructs chemically and genetically linked either to a variety of targeted ligands or antibodies against cell surface receptors. 12, [18] [19] [20] [21] [22] [23] [24] [25] Results from studies using adaptor molecules have shown a 10-20-fold increase in transgene expression in target tissues in vivo. 24 Studies have also established correlations between augmented gene transfer and cell-surface receptor density, and demonstrated a substantial reduction of reporter gene expression in the liver compared with untargeted vector. 12, 23 Preliminary evidence also indicates high stability and good in vivo performance for complexes involving Ad particles and adaptor molecules. 18, 22, 26, 27 These early results are promising, but additional studies need to be performed to achieve optimal retargeting of Ad vectors for cancer therapy or imaging.
Angiogenesis is an important process in the progression of solid tumors. The relatively disorganized tumor neovasculature might provide increased Ad access in the tumor microenvironment, 28, 29 and the utility of this effect could also be enhanced by the addition of genetic and/or physical detargeting/retargeting approaches. Tumor-specific endothelial markers of angiogenesis (TEMs) have been extensively characterized, and are rapidly being incorporated into targeted therapy strategies. Phosphatidylserine (PS) and other negatively charged phospholipids are usually restricted to the cytosolic side of cell membranes in most cells. [30] [31] [32] [33] However, anionic phospholipids become exposed on both tumor cells and tumor vascular endothelium, but not on normal vascular endothelium in mice, making PS one of the most specific tumor markers discovered to date. 30, 31 Bavituximab is a chimeric antibody that targets exposed PS by stabilizing a complex of two b2-glycoprotein I molecules that are attached to PS at the cell surface. 30, 31, 34, 35 Mouse versions of this antibody (3G4 and 2aG4) have been shown to inhibit tumor growth in multiple animal models, and a recent study shows that clear images of subcutaneous prostate tumors can be obtained in rats following tail vein injection of isotopically-labeled bavituximab. 36 Preliminary evidence indicates that antibodies against PS are rational candidates for incorporation into bispecific adaptor molecules designed to retarget Ad vectors to tumor tissue. The anti-microtubule chemotherapeutic docetaxel also induces the externalization of PS on several cell types, and has been shown to significantly improve antitumor activity in mice when combined with 3G4 in MDA-MB-435 tumor models. 34 The use of docetaxel in combination with PS-retargeted vectors could theoretically improve the delivery of Ad vectors for imaging or therapeutic purposes.
Vascular disrupting agents (VDAs) are a relatively new group of compounds that show selective disruption of tumor vasculature, primarily through the depolymerization of microtubules in the endothelial cytoskeleton. 37 Several VDAs such as combretastatin are currently in clinical development, and early results show that these agents have great potential for normalizing neovasculature, thereby reducing blood flow specifically in tumors. Although the exact mechanism of this specificity has not been firmly established, the predominant theory is that the immature and fragile nature of tumor vasculature makes it particularly susceptible to this type of therapy. 38 However, these strategies can also have undesirable effects, by potentially selecting for more malignant cells, inducing cellular adaptations that promote tumor invasion, or restricting the access of therapeutic agents to the tumor. 39 The clinical use of anti-angiogenics and VDAs therefore needs to be carefully considered in the context of other therapeutic decisions, and many researchers have suggested that the timing of antiangiogenic therapy with other agents could be an important consideration. 40 Characteristics of tumor vasculature could also affect Ad gene delivery for therapy or imaging purposes. Previous results in our lab have suggested that the disorganized and leaky nature of tumor blood vessels might improve Ad access to tumors in mice, 28 so VDAs could be valuable for resolving the contributions of irregular tumor vasculature on Ad transduction efficiency.
In this study, we sought to explore strategies for the detargeting and retargeting of Ad vectors to develop a platform of tumor imaging agents using luciferase as an optical reporter. Various approaches for transductional retargeting with or without the administration of ancillary agents were evaluated to improve the tumor specificity of Ad-mediated luciferase delivery and expression in vitro and in vivo.
Materials and methods

Adenoviral expression vectors
AdCMVluc, with sequences from the human CMV immediate early promoter has been previously published. 41 For construction of the luciferase vector containing mutations in the CAR and HSG binding sites (AdCMVLucHSG À CAR À ), the QuickChange mutagenesis protocol (Stratagene, La Jolla, CA) was used to modify residues in the fiber knob previously shown to be involved in native CAR and HSG interactions. [42] [43] [44] Mutations in K420A, K417G in fiber knob domain were used to ablate native CAR interactions, and 91 
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94 at the end of the third repeat in the fiber shaft was mutated to 91 EAGA 94 to reduce HSG-mediated interactions. These mutations were incorporated into the recombinant viral genome cloned into pTG3602CMVlux (pTG3602 containing a CMV luciferase transgene inserted into E1) using homologous recombination in E. coli BJ5183. 45 The entire fiber gene was then sequenced to verify the mutations. Virus was reconstructed from the plasmid by excising the viral genome with PacI and transfection into 911 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
Construction of the NapC2 expressing Ad vector (AdNapC2) was performed by fusing complementary DNA fragments encoding the secretory signal peptide from human tissue plasminogen activator with the mature protein coding region of NapC2 under the control of the CMV promoter, 46 followed by standard homologous recombination 1 for incorporating this expression cassette into the viral genome.
All viruses were propagated and purified as previously described. 1 Briefly, large-scale preparations were grown on 911 cells, harvested and purified sequentially on CsCl step gradients and Sepharose CL-4B columns equilibrated with Tris-buffered isotonic saline (137 mM NaCl, 5 mM KCl, 10 mM Tris-HCl pH7.4, 1 mM MgCl 2 ). Virus concentration was determined by optical density, with 1.0 A 260 equal to 1 Â 10 12 particles per ml. Viruses were stored frozen at À80 1C after the addition of 10% glycerol at concentrations between 10 12 and 10 13 particles per ml until use.
Production of soluble fiber knob Soluble fiber knob was expressed in E.coli as a six histidine N-terminal-tagged protein using the commercially available plasmid expression vector pQE30 from Qiagen (Valencia, CA). Expression and purification of the knob protein to homogeneity in mg quantities was carried out in a straightforward manner using IPTG induction, salt/detergent extraction of the soluble knob and affinity purification on a Ni-agarose column according to the supplier's protocols. Purified protein was dialyzed versus Tris-buffered isotonic saline containing 10% glycerol and stored frozen at À80 1C.
Cell culture
Clonal HT1080 fibrosarcoma cells and MDA-MB-435 melanoma cells (originally thought to be a breast cancer line) were propagated in Dulbecco's minimal essential medium containing 10% fetal bovine serum. Infections of cells in vitro were performed with purified stocks of viruses diluted into Dulbecco's minimal essential medium containing 2% fetal bovine serum using equivalent titers in particles per ml for infection. Cell cultures were infected for 1 h at 37 1C, and incubated overnight before cells were harvested and luciferase activity determined to assess transduction efficiency.
Construction of the bispecific antibody
Monoclonal antibodies 7H11 directed against the Ad5 fiber knob 25 and bavituximab directed against the PS:b2-glycoprotein I complex 26 were used to construct the bispecific antibody (bsAb). The bispecific F(ab 0 ) 2 antibody derivative (bsAb) with dual specificity against the Ad fiber knob and PS was constructed by generating a natural cysteine disulfide linkage between two Fab 0 fragments, using their hinge region SH groups as previously described. 47 The control antibody for the bispecific detargeting/retargeting experiments consisted of a chimeric antibody of bavituximab partnered with the non-neutralizing anti-fiber knob monoclonal 2A12. Antibody purity was confirmed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis followed by visualization with Coomassie Brilliant Blue, and concentration was determined by A 280 . The dual specificity of F(ab 0 ) 2 heterodimers was then confirmed by demonstrating the ability of the product to bind to both target antigens in ELISAs and cell-binding assays, as previously described. 48 
Animal experiments
All animal experiments were approved by the Institutional Animal Care and Use Committee. Female mice were used preferentially for HT1080 tumor cell implantation, although not exclusively. Mice were injected subcutaneously with 3-5 Â 10 6 cells suspended in 0.5 ml Dulbecco's minimal essential medium on the dorsal flank. Tumors were allowed to grow until 0.4-0.8 cc in size as measured by calipers, at which time either purified adenovirus or adenovirus pre-incubated with either the bispecific or control antibody at a fiber:bsAb ratio of 1:1 was injected via the tail vein at doses of 10 10 or 10 11 particles per mouse.
To determine the effect of docetaxel administration, 0.2 ml of 10 mg per ml of docetaxel was administered intraperitoneally at 48 h before virus injection. For determination of the effects of fiber knob pre-injection on gene transfer efficiency, 10-20 mg of soluble fiber knob were pre-injected via the tail vein 5-10 min before injection of adenovirus or Ad:bsAb complex. To assess the effect of combretastatin 1-phosphate (CA1P, Oxigene, Waltham, MA) on luciferase gene transfer and expression, 25 mg per kg of body weight of CA1P dissolved in normal saline was injected intraperitoneally either 6 h before or 48 h following injection of adenovirus.
Luciferase imaging and biochemical determination At 3 days after injection of adenovirus or Ad:bsAb complex, mice to be imaged were anaesthetized with isoflurane and injected subcutaneously with luciferin (0.1 mg per g of body weight). Whole-body luciferase activity was imaged with a Lumina bioluminescence imaging system (Caliper Biosciences, Hopkinton, MA). Total tumor light flux was quantified using the instrument's imaging software (Caliper Biosciences). Mice were subsequently killed and major organs and tumors removed for biochemical determination of luciferase activity performed as previously described. 28 Viral DNA content in tissues was measured by real-time PCR detection of the adenovirus type five hexon gene as previously described. 28 
Statistical analyses
SigmaStat for Windows v3.11 was used to perform Mann-Whitney rank-sum test analyses for pairwise comparisons between individual treatment groups and controls.
Results
Effect of soluble fiber knob pre-injection on adenoviral gene transfer and expression in tumor-bearing mice Soluble fiber knob protein is an effective competitor for adenovirus binding to cell surface CAR. To evaluate the relative effects of knob pre-injection on Ad transduction and transgene expression in various tissues in vivo, 10 10 particles of AdCMVLuc was administered via tail-vein injection to HT1080 tumor-bearing mice either with or without pre-injection of a saturating quantity of a soluble fiber knob construct. 49, 50 Previous estimates of the initial binding capacity of a similar knob construct in a typical mouse liver was B3.1 mg. 50 On the basis of this work, we used a three-to sixfold excess of this amount per mouse to achieve saturation. Animals were killed after 3 days and both luciferase gene delivery and expression were assessed using biochemical methods. Results show that mean luciferase expression in both the liver and tumor (expressed as relative light unit (RLU) per mg of wet tissue) was unaffected by fiber knob pre-injection ( Figure 1a) . However, the tumor/liver ratio of luciferase expression was slightly lower (nearly twofold) when fiber knob was pre-injected (P ¼ 0.018), consistent with a minor effect of blocking CAR-mediated virus uptake in either tissue. A small reduction in gene delivery as assessed by viral DNA content per mg of tissue was observed in tumors of mice pre-injected with fiber knob compared with controls (P ¼ 0.043; Figure 1b) , and the expression of luciferase per viral DNA copy was also slightly reduced in tumor tissue of mice receiving fiber knob pre-injection (P ¼ 0.028; data not shown). 
Effects of detargeting adenoviral vectors by mutation of the CAR and HSG binding sites
Previous results have demonstrated significant effects of individual fiber mutations on gene transfer and expression in multiple tissues of normal mice. 43, 51 Mutations in both the HSG and CAR binding sites of the Ad fiber shaft and fiber knob, respectively, were therefore made to assess the contribution of HSG and CAR-mediated interactions on Ad infection in tumor-bearing mice. HT1080 tumorbearing mice received tail-vein injections of 10 10 or 10 11 particles of wild-type AdCMVluc or mutant AdCMVluxHSG À CAR À , and luciferase gene delivery and expression were assessed in various tissues using biochemical methods. Significant reductions in luciferase expression were observed for AdCMVluxHSG À CAR À compared with AdCMVluc in both liver (P ¼ 0.03) and tumor (P ¼ 0.003), an effect that was more pronounced in both tissues (Po0.001) using 10 11 viral particles ( Figure 1c ). Significant differences in tumor to liver ratios were not seen, which was expected due to overall reductions in luciferase expression in all tissues for the mutated virus compared with the wild type. Indeed, infection of HT1080 tumor cells in vitro by the two viruses showed that the mutant virus required a 30-fold higher concentration of viral particles to achieve luciferase expression equivalent to that of the wild-type virus (data not shown). Although significant differences in Ad gene delivery were not observed at the 10 10 viral dose, a significant reduction in viral DNA copy per mg of tissue was observed in the liver (P ¼ 0.004) and a significant increase in the tumor/liver ratio was also noted using the HSG À CAR À vector compared with AdCMVLuc at the 10 11 dose (P ¼ 0.027; Supplementary Figure 1A) . Significant reductions in luciferase expression per viral DNA copy were also observed for mutated virus compared with AdCMVluc in liver and tumor at the 10 10 viral particle dose (P ¼ 0.017 and P ¼ 0.002, respectively), and in tumor at the 10 11 dose (P ¼ 0.002; Supplementary Figure 1B ). These effects are most likely due to reduced liver inflammation using the detargeted virus.
Reducing liver tropism and improving tumor specificity of adenovirus using NapC2 Various reports indicate that liver tropism is largely due to interaction of the adenovirus type five hexon protein with serum coagulation factors. [6] [7] [8] [9] [10] As this mode of liver uptake can be reduced by the nematode anti-coagulant protein NapC2, 7 we tested the ability of recombinant NapC2 to block liver gene transfer and expression in mice. An Ad vector incorporating the CMV promoter was used to systemically express the NapC2 protein with a signal peptide from tissue plasminogen activator to direct protein secretion from infected cells into the circulation. Varying doses of AdNapC2 were first injected into mice and after 2 days, the ability of 10 11 particles of AdCMVluc to transduce liver was assayed. Results show substantially reduced AdCMVLuc gene expression in the liver at AdNapC2 doses above 10 9 particles (Figure 2a ). Similar reductions in gene delivery (viral DNA per mg of tissue) were also observed in the liver at higher doses of AdNapC2 (Figure 2b ). Together these data suggest that the systemic anti-coagulant NapC2 effectively reduced liver tropism and transgene expression.
An alternative approach for delivering NapC2 is to use serum from mice pre-injected with AdNapC2 as a source of the anti-coagulant factor. HT1080 tumor-bearing mice were pre-injected with 100 ml of serum collected from mice that had previously received 3 Â 10 10 particles of AdNapC2. Following serum injection, these mice received 10 11 particles of AdCMVLuc and luciferase expression was assessed after 3 days. Results showed significant reductions in luciferase expression for all tissues tested in mice that received pre-injections of NapC2 serum compared with those receiving 10 11 particles of AdCMVLuc alone (Figure 2c ). This effect was most pronounced in the liver, however, which showed a 1800-fold reduction in mean luciferase expression when NapC2 serum was pre-injected (Po0.001 by pairwise comparison with AdCMVLuc alone). The lung had the next greatest reduction in mean luciferase expression by NapC2 serum compared with AdCMVLuc alone (160-fold; Po0.001 by pairwise comparison), and the mean luciferase expression in tumor was reduced 65-fold (P ¼ 0.002). As a result, the tumor specificity of luciferase expression per mg of tissue indicated by the tumor/liver ratio was significantly increased sixfold in mice receiving NapC2 serum preinjection as compared with mice receiving AdCMVLuc alone (P ¼ 0.018).
There were also significant reductions in gene delivery (viral DNA copy per mg tissue) for all tissues tested in mice receiving pre-injections of NapC2 serum compared with mice receiving AdCMVluc alone (data not shown), suggesting that the overall reduction in luciferase expression is a result of lower transduction efficiency due to NapC2 interference. Significant reductions in luciferase expression per viral DNA copy in tumor (P ¼ 0.032) and liver (P ¼ 0.009) were also observed, which could also help to explain the lower luciferase expression due to a decreased inflammatory response in these tissues (data not shown). Overall levels of luciferase expression and gene delivery in mice pre-injected with NapC2 serum and subsequently with 10 11 particles AdCMVLuc were quantitatively similar to those observed in mice receiving a dose of 10 10 particles AdCMVLuc in all tissues tested, which indicates an overall effective decrease of one log infectivity for the Ad vector as a result of NapC2 preinjection.
Mice with HT1080 tumors were also pre-injected with 3 Â 10 9 particles of AdNapC2 to permit systemic expression of the anti-coagulant protein, then injected with 10 11 particles of AdCMVluc after 2 days to compare the ability of endogenously produced NapC2 to the NapC2 serum in reducing liver infectivity. Luciferase expression per mg of tissue was similar in these mice compared with those receiving NapC2 serum, with no significant differences observed in any tissue by pairwise analysis (data not shown), with the exception that there was a 35-fold increase in luciferase expression per mg of liver in mice receiving AdNapC2 compared with those that received NapC2 serum (P ¼ 0.029). This is probably a result of increased liver inflammation resulting from the higher viral dose when two viruses were administered. However, in all other tissues, both methods of anti-coagulation (endogenous and exogenous) seem to have similar effects on the expression of an adenovirally delivered transgene.
Retargeting adenoviral vectors using a bispecific antibody directed to negatively charged phospholipids Transductional targeting of Ad vectors is an attractive strategy to reduce liver infection and achieve greater tumor specificity for transgene delivery, and PS is a potentially useful target based on high levels of PS exposure on both tumor cells and tumor vasculature. 30, 31 We therefore, evaluated the efficacy of a bsAb capable of retargeting AdCMVluc to tumor cells. First, various amounts of bsAb were mixed with purified Ad particles to obtain different ratios of bsAb to Ad fiber. Equivalent numbers of bsAb-targeted viral particles were then used to infect HT1080 and MDA-MB-435S tumor cells in vitro, which provided an estimate of the optimal ratio for further in vivo experiments. The addition of soluble fiber knob to cells before virus infection was used to block fiber binding to CAR, and soluble knob blocked 490% of wild-type virus infectivity on HT1080 cells (Figure 3a) . The addition of bsAb increased Ad infectivity of HT1080 cells about sevenfold, which was unaffected by the addition of soluble knob.
This indicates the ability of bsAb to effectively retarget virus by a mechanism that is independent of knob:CAR interactions. Lower bsAb:fiber ratios were clearly more effective at retargeting adenovirus, and excess bsAb apparently reduced overall infectivity.
Knob had no effect on wild-type virus binding to MDA-MB-435S cells, suggesting that wild-type virus entry into these cells is largely CAR independent. This was expected based on previous studies showing a lack of CAR expression and a primarily integrin-mediated mechanism of Ad entry in MDA-MB-435S cells. 52, 53 There was a greater increase in MDA-MB-435s cell transduction (180-fold) by bsAb-retargeted virus in comparison with HT1080 cells, and again, soluble knob protein had no effect on bsAb-retargeted virus infectivity. This can in part be attributed to a lack of CAR-dependent transduction of the breast cancer cells by wild-type virus. Again, lower bsAb:fiber ratios were clearly more effective at retargeting adenovirus, and excess bsAb apparently reduced overall infectivity even more in MDA-MB-435s cells than HT1080 cells. Therefore, a 1:1 bsAb:fiber ratio was used for preparing Ad:bsAb complexes in all subsequent in vivo experiments.
The efficacy of bsAb-mediated retargeting of Ad vectors was next assessed in HT1080 tumor-bearing mice by administering Ad:bsAb compared with AdCMVluc via tail-vein injection. Mice were killed after 3 days and both luciferase gene expression and delivery were assessed in various tissues using biochemical methods. Results show significant decreases in luciferase expression in the heart (Po0.001) and spleen (P ¼ 0.026) for Ad:bsAb compared with AdCMVluc alone (Figure 3b ), which suggests bsAbmediated detargeting of virus from these tissues. There was also a significant increase in viral targeting to the tumor with the addition of Ad:bsAb compared with AdCMVluc (P ¼ 0.01), but this increase was less than twofold and there was no significant change in tumor/ liver ratio. Viral copy number per wet weight of tissue was also decreased for Ad:bsAb compared with AdCMVluc for lung (P ¼ 0.006) and spleen (P ¼ 0.003), although there was no change in heart, kidney, liver, tumor or tumor/liver ratio (Figure 3c ). There were also small increases in mean specific activity of expression (RLU/ viral DNA copy) in lung (11-fold, Po0.001), liver (2.5-fold, P ¼ 0.028) and tumor (4.5-fold, P ¼ 0.006), and a small decrease in heart (3.8-fold, P ¼ 0.038) for Ad:bsAb compared with AdCMVluc (data not shown).
Effect of soluble fiber knob pre-injection on bsAb-retargeting of adenoviral vectors in vivo To investigate specific Ad molecular interactions in the context of bsAb-retargeted virus, we next evaluated the effects of pre-injected saturating amounts of soluble fiber knob on the infectivity of bsAb-AdCMVluc in the liver compared with tumor in vivo. Both mean luciferase expression (Supplementary Figure 2A) and gene copy number per mg of tissue (Supplementary Figure 2B) was increased three to four fold in the tumor by pre-injection of soluble fiber knob compared with controls (P ¼ 0.003 for both by pairwise rank-sum comparison). There were no significant differences found in luciferase expression or gene delivery in liver or tumor/liver ratio due to pre-injection of fiber knob.
Docetaxel improves bsAb-retargeting of adenoviral vectors in tumor-bearing mice
The anti-microtubule agent docetaxel has previously been shown to induce the externalization of PS on several cell types, in addition to improving the antitumor activity of an anti-PS antibody in a murine tumor model. 34 We therefore evaluated the ability of docetaxel to improve bsAb-retargeting of AdCMVluc to tumors in vivo. Because the antitumor activity of docetaxel alone complicates interpretation of in vivo data, all mice received systemic treatment with docetaxel 2 days before intravenous delivery of 10 10 particles of AdCMVluc complexed with either the bsAb or a control antibody. Mice were killed after 3 days and both luciferase gene delivery and expression were assessed using both bioluminescent imaging and biochemical methods.
In vivo imaging of luciferase activity showed an increase in tumor expression in Ad:bsAb-treated mice as compared with controls (representative animals shown in Figure 3d ). The mean photon flux increased nearly 10-fold from 1.3 Â 10 7 to 1.2 Â 10 8 in doectaxel-treated mice given Ad:bsAb as compared with the control antibody, which was statistically significant (P ¼ 0.015). Biochemical results also indicate significantly increased luciferase expression per wet weight of tissue in the liver (4.5-fold, P ¼ 0.02), spleen (4.5-fold, P ¼ 0.003), tumor (50-fold, P ¼ 0.002) and the tumor/liver ratio (9-fold, P ¼ 0.026), whereas the heart showed a significant decrease (3-fold, P ¼ 0.02) in mice that received Ad:bsAb compared with the Ad:control antibody (Figure 3e ). The differences are primarily due to a dramatic reduction in gene expression in Ad:control antibody-treated mice given docetaxel, as the mean luciferase expression in tumors of mice treated with docetaxel were no higher than those in mice given the same Ad:bsAb without docetaxel (Figure 3b ).
Significant increases in viral DNA copy per mg tissue was also observed for kidney (P ¼ 0.034), liver (P ¼ 0.011) and tumor (P ¼ 0.011), and a significant decrease was observed in spleen (P ¼ 0.001) in mice receiving Ad:bsAb compared with controls (Figure 3f ). Changes in mean values of viral copy per mg in liver (three-to fourfold) and tumor (nearly 30-fold) correlated well with increases in mean RLU per mg for these tissues, indicating that increased luciferase expression is likely due to improved transduction efficiency for the bsAb-retargeted virus compared with control virus in the context of docetaxel treatment. No significant increase in luciferase expression per viral DNA copy was observed in any tissues except for spleen (data not shown), which likely explains the increase in luciferase expression despite a reduction in DNA copy number in this tissue.
Effect of combretastatin A-1-P (CA1P) on tumor specificity following AdCMVluc administration Combretastatin has been shown to specifically disrupt tumor vasculature. 37 Previous results in our lab also suggest that the disorganized and leaky vasculature normally present in solid tumors can increase Ad access to tumor tissue. 28 We therefore, evaluated the effects of CA1P treatment given either 6 h before or 48 h after systemic administration of 10 10 particles of AdCMVluc. Results show a highly significant decrease in luciferase expression per mg of tissue in tumor (Po0.001) and a highly significant increase in the liver (Po0.001) following pretreatment with CA1P (Figure 4a ). These changes in RLU per mg translated into a 160-fold decrease in tumor specificity shown by the tumor/liver ratio of RLU per mg values (Po0.001). By contrast, luciferase expression in tissues of mice given combretastatin at 48 h after receiving AdCMVluc was indistinguishable from controls. This suggests that pre-treatment effects are due to decreased tumor accessibility to virus in mice whose tumor vasculature had been normalized by CA1P pretreatment. Significant changes in viral DNA per mg of tissue were not observed in liver or tumor following CA1P pretreatment compared with controls (Figure 4b ), indicating that the difference in luciferase expression in liver observed for CA1P pretreatment is due to effects other than a change in transduction frequency. Indeed, luciferase expression normalized to viral DNA copy number (Figure 4c ) is substantially higher in the liver (Po0.001) following CA1P pretreatment compared with controls, whereas expression per DNA copy was lower in the tumor (Po0.001). Increased CMV-driven expression in the liver in addition to decreased tumor expression following CA1P treatment, are the primary factors resulting in decreased tumor specificity following CA1P pre-treatment.
The effects of CA1P are readily visualized by correlating the total tumor photon flux quantified by bioluminescent imaging (Figure 4d ) with the biochemically determined luciferase activity. Similar decreases in both total photon flux and luciferase activity determined biochemically are seen in the tumor following pretreatment with CA1P as compared with controls receiving no CA1P (Figure 4e ). In mice receiving CA1P at 48 h after administration of virus, however, only tumor photon flux is decreased as compared with control mice. This differential effect is likely due to the decreased tumor availability of the luciferin given to mice immediately before bioluminescent imaging, whereas biochemically determined luciferase expression is unaffected because the full complement of virus has been delivered before CA1P-mediated disruption of the tumor vasculature.
Discussion
Ad technology remains a promising method to deliver transgenes to tumor cells for imaging or therapeutic purposes, but a number of complicating factors still need to be addressed. A central issue is the broad native tropism of systemically administered adenovirus, including the high levels of liver infectivity widely observed for unmodified virus. 11 This represents a substantial problem for the clinical development of Ad vectors, because high liver infectivity could result in hepatic toxicity and also reduces the amount of adenovirus available for infecting tumor cells. To investigate various methods for reducing liver infection, we first assessed the ability of soluble fiber knob to compete for adenovirus binding to CAR and alter the tropism of wild-type adenovirus. Pre-injection of knob protein, however, had little effect on the infectivity of wild-type virus in the liver or tumor in our investigation. Other interactions such as those between HSGs and the Ad shaft have also been shown to be important for liver infection. 13 To evaluate the effects of ablating multiple Ad interactions, we also evaluated an Ad construct with dual mutations in the CAR and HSGbinding sites located in the fiber knob and fiber shaft, respectively. Although HSG-CAR-modified virus resulted in significantly lower luciferase expression compared with wild type, similar reductions were also seen in all other tissues including tumor. Our results therefore, suggest that the elimination of both CAR and HSG interactions is unlikely to improve the tumor specificity of Ad infection.
Because of previous work by others suggesting the crucial importance of FX-mediated interactions for Ad liver infectivity, we also evaluated the ability of a FXbinding anti-coagulant protein (NapC2) for reducing liver transduction and improving the tumor specificity of Ad infection. Preliminary data in non-tumor-bearing animals indicated that NapC2 expression effectively reduced subsequent Ad infection in the liver, but data in tumorbearing animals showed a global reduction of Ad infectivity across all tissues tested. This effect was most pronounced in the liver, in agreement with previous studies showing the greater importance of FX-mediated interactions in Ad tropism to hepatocytes. 6, 7, 10, 15, 16, 54 Consistent with our results, these data also suggest that FX-mediated interactions are important for Ad infection in epithelial cells, spleen and lung, in addition to several types of tumor cells. [6] [7] [8] [14] [15] [16] 55 To our knowledge, ours is the most extensive in vivo analysis of the effects of NapC2 on subsequent Ad infection in a variety of tissues. Our data, when combined with previous studies, suggests that Ad vectors might use FX-mediated interactions for infecting more types of cells and tissues than previously believed. Thus, strategies designed to ablate FX-dependent Ad infection of the liver need to be combined with additional retargeting strategies to improve the overall therapeutic index of these approaches.
Chemical retargeting of Ad vectors using bispecific adaptor molecules is an attractive option to reduce undesired native interactions and improve the tumor specificity of Ad transgene delivery. We evaluated a bsAb directed against Ad fiber knob and PS for its ability to retarget wild-type adenovirus to tumor tissue in vivo, based on the tendency of tumor endothelium to externalize PS compared with normal tissue. 30, 31 The small but significant increase in luciferase expression we observed using bsAb compared with wild-type virus alone in vivo was largely expected based on in vitro results. Interestingly, gene delivery assessed by viral DNA copy per mg of tissue was lower in all tissues including tumor with the addition of bsAb compared with controls. In fact, improved transcription with the addition of bsAb rather than increased transduction seemed to be the primary reason for the increase in tumor luciferase expression. This was unexpected based on the physical retargeting method, which should have led to improved tumor specificity exclusively by increasing the frequency of viral gene delivery in tumor tissue. The addition of soluble fiber knob before systemic administration of bsAb-retargeted virus, however, improved both luciferase expression and gene delivery in tumor tissue, suggesting that reducing viral interactions with non-target tissues may increase the amount of bsAb-retargeted virus available for tumor cell infection. Experiments performed on the background of docetaxel treatment showed an even greater improvement in mean transgene expression in the tumor and a significant improvement in tumor specificity for bsAb-retargeted virus. In addition, docetaxel resulted in a significant increase in viral gene delivery in the tumor, suggesting that doectaxel increased the externalization of PS and improved PS-directed Ad retargeting. The mean values of luciferase expression in tumor were quantitatively similar to those observed with no docetaxel treatment, however, so the ability of docetaxel to substantially increase Ad retargeting of tumors is difficult to interpret.
Previous results from our lab suggest that the disorganized and leaky tumor vasculature might improve Ad access to tumors in mice, 28 so we further investigated this possibility using the tumor-specific vascular disrupting agent CA1P. Pre-treatment with CA1P clearly decreased luciferase expression in tumors, whereas treatment with CA1P at 2 days following adenovirus administration had no effect. This indicated that disrupting tumor vasculature significantly restricts viral access to tumors, but has little effect on transgene expression following the delivery of wild-type virus to tumor cells. CA1P pre-treatment had the opposite effect in the liver, showing an increase in liver transgene expression. This could indicate that virus excluded from the tumor because of vascular disruption became available to infect other tissues such as liver. The higher observed luciferase expression per viral DNA copy in the liver, however, could also be partially explained by increased hepatic inflammation driving expression from the inflammatory responsive CMV promoter. The correlation of biochemical and bioluminescent data also showed that vascular disruption apparently reduces tumor access to luciferin. Unlike adenovirus, luciferin is a small molecule substrate, access of which to the tumor was substantially restricted following CA1P administration. This provides additional evidence that the timing of anti-vascular agents could be important for efficacy when combined with cytotoxic or targeted therapies, and these results overall suggest that issues related to the immediate tumor microenvironment will be important considerations during the optimization of Ad technology for therapeutic or imaging purposes.
Modified Ad vectors have great potential for the tumor-specific delivery of genes expressing therapeutic or imaging agents, but more effective methods for detargeting adenovirus from their native interactions and improving tumor specificity must be developed.
Results from this investigation demonstrate that a bsAb against the Ad fiber knob and PS can be effective for retargeting adenovirus to tumor cells, and that the coadministration of docetaxel to increase PS expression on tumor vasculature or the use of competitive inhibitors to reduce native interactions with non-target tissues improved the overall effectiveness of this approach. The use of VDAs such as CA1P for modifying the tumor vasculature, as well as the transcriptional microenvironment of the tumor to drive the expression of Ad-delivered genes also needs further evaluation. The complex and ever-changing landscape of tumor biology suggests that Ad therapy will require optimization for particular tumors and physiological conditions, and results from this study support the idea that issues related to tumor microenvironment will be important for the continued development of Ad-based cancer therapy.
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